机构地区:[1]湖北中医药大学 [2]湖北省武汉市第一医院消化内科,湖北武汉430022
出 处:《河北中医》2017年第11期1637-1640,1645,共5页Hebei Journal of Traditional Chinese Medicine
摘 要:目的观察茵黄清木合剂对肝胆湿热型免疫耐受期乙型肝炎病毒(HBV)携带者的治疗效果,并评价其疗效。方法将120例HBV携带者随机分为2组。治疗组60例,给予茵黄清木合剂治疗;对照组60例,不使用任何药物治疗,定期随访,监测患者肝功能、HBV载量及标志物水平变化等。2组均观察治疗3个月,停药后再连续观察3个月。分别观察2组治疗3个月后及停药3个月后的疗效变化情况,并比较2组治疗前、治疗3个月后及停药3个月后HBV-DNA水平及HBV e抗原(HBeAg)转阴变化情况。结果治疗后3个月后,治疗组总有效率90.0%,对照组总有效率66.7%,停药3个月后治疗组总有效率91.7%,对照组总有效率65.0%,治疗组治疗3个月后及停药3个月后总有效率均高于对照组(P<0.05);对照组治疗3个月后及停药3个月后HBV-DNA水平与本组治疗前比较无明显变化(P>0.05),治疗组治疗3个月后及停药3个月后HBV-DNA水平与本组治疗前比较均有明显降低(P<0.05),且低于对照组同期HBV-DNA水平(P<0.05);治疗3个月后治疗组HBeAg转阴2例,对照组转阴1例,停药3个月后治疗组HBeAg转阴3例,对照组转阴1例,2组治疗3个月后及停药3个月后HBeAg转阴情况比较差异均无统计学意义(P>0.05)。结论茵黄清木合剂治疗肝胆湿热型免疫耐受期HBV疗效确切,可明显改善患者临床症状、体征,提高临床疗效,降低HBV-DNA水平,降低病毒复制,安全可靠,具有明显的优势。Objective To observe the clinical effects of Yinhuang-muqing mixture on hepatitis B virus( HBV) carrier with liver and gallbladder damp-heat type in immune tolerant phase,and evaluate its efficacy.Methods 120 HBV carriers were randomly divided into two groups. 60 cases in the treatment group were treated by Yinhuang-muqing mixture. And 60 cases in the control group without any drug treatment,regular follow-up,and liver function,HBV load and the changes of marker level were monitored. 2 groups were observed and treated for 3 months,then continue observed for 3 months after drug withdrawal. The changes of curative effect after treatment 3 months and after drug withdrawal 3 months were observed respectively in two groups. The changes of HBV-DNA levels and Hepatitis Be Antigen( HBeAg) negative were compared before and after treatment 3 months and after 3 months drug withdrawal in two groups. Results After treatment 3 months,the total effective rate was 90. 0% in the treatment group,and 66. 7% in the control group. The total effective rate was 91. 7% in the control group and65. 0% in the control group after drug withdrawal 3 months. The total effective rates after treatment 3 months and after drug withdrawal 3 months in the treatment group were higher than that in the control group( P < 0. 05). There was no statistical difference on the level of HBV-DNA between before and after treatment 3 months,between before and after drug withdrawal 3 months in the control group( P > 0. 05). The levels of HBV-DNA after treatment 3 months and after drug withdrawal 3 months were reduced in the treatment group( P < 0. 05),and which in the treatment group was lower than that in the control group at the same period( P < 0. 05). After treatment 3 months,2 cases of HBeAg were turning negative in treatment group,and 1 case of HBeAg was turning negative in control group. After drug withdrawal 3 months,3 cases of HBeAg were turning negative in treatment group,and 1 case of HBeAg was turning negative in control group. There was no statistica
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...